Back

Beyond age - A prospective cohort study on the impact of frailty, malnutrition and disability on management and survival in transthyretin cardiac amyloidosis

31 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Prognostication and treatment of transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Carlo Fumagalli

University of Campania Luigi Vanvitell, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis
Doctor K. Knoll (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Impaired right ventricular free wall strain predicts mortality in patients with stabilizer-treated transthyretin amyloid cardiomyopathy.
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy
Doctor A. Mejren (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Identifying predictors and cutoff values for pacemaker implantation in ATTR patients
Doctor S. Istratoaie (Cluj Napoca, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Prognostication and treatment of transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

31 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study
thumbnail
Congress Presentation
The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy
thumbnail
Congress Presentation
Frailty and associated outcomes in patients with transthyretin cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources